ORGANIC
LETTERS
XXXX
Vol. XX, No. XX
000–000
Carboxamide versus Sulfonamide in
Peptide Backbone Folding: A Case Study
with a Hetero Foldamer
Veera V. E. Ramesh,† Sangram S. Kale,† Amol S. Kotmale,‡ Rupesh L. Gawade,§
Vedavati G. Puranik,§ P. R. Rajamohanan,‡ and Gangadhar J. Sanjayan*,†
Division of Organic Chemistry, Central NMR Facility, and Center for Materials
Characterization, National Chemical Laboratory, Dr. Homi Bhabha Road,
Pune 411 008, India
Received January 30, 2013
ABSTRACT
Strikingly dissimilar hydrogen-bonding patterns have been observed for two sets of closely similar hetero foldamers containing carboxamide and
sulfonamides at regular intervals. Although both foldamers maintain conformational ordering, the hydrogen-bonding pattern and backbone
helical handedness differ diametrically.
Sulfonamides are an important class of compounds
which are widely used in the design of diverse classes of
drug candidates.1 In view of their biomedical importance,
sulfonamide building blocks have been incorporated into
many peptides.2 Although both come under the class of
amides, carboxamide and sulfonamide have strikingly
different hydrogen-bonding and geometrical preferences:
(i) as compared to carboxamide NH, the sulfonamide NH
is more acidic, resulting in its better participation in
H-bonding events; (ii) sulfonamide has two H-bonding
acceptor oxygens; (iii) the sulfonamides have a favored
dihedral angle, ω e 90°, as opposed to carboxamides
which usually favor a planar conformation with ω e
180°; and (iv) the bond length SÀN in sulfonamide is
greater than CÀN in carboxamide, thus sulfonamide has
low SÀN rotation barrier as compared to carboxamide.3
Intrigued by their distinctly different conformational
propensities, we were interested in investigating the effect
on swapping carboxamide with sulfonamide in foldamers.
In order to realize this goal, we designed two sets of hetero
foldamers4 featuring regularly repeating R,β,R-tripeptide
building blocks of the structure Pro-Xaa-Aib (Figure 1).
Whereas 1, 3, and 5 feature anthranilic acid (Xaa = Ant,
† Division of Organic Chemistry.
‡ Central NMR Facility.
(3) Radkiewicz, J. L.; McAllister, M. A.; Goldstein, E.; Houk, K. N.
J. Org. Chem. 1998, 63, 1419.
§ Center for Materials Characterization.
(1) (a) Supuran, C. T.; Scozzafava, A. Med. Res. Rev. 2003, 23, 535.
(b) Maren, T. H. Annu. Rev. Pharmacol. Toxicol. 1976, 16, 309.
(2) (a) Gennari, C.; Salom, B.; Potenza, D.; Williams, A. Angew.
Chem., Int. Ed. Engl. 1994, 33, 2067. (b) Gennari, C.; Salom, B.; Potenza,
D.; Longari, C.; Fioravanzo, E.; Carugo, O.; Sardone, N. Chem.;Eur.
J. 1996, 2, 644. (c) Liskamp, R. M. J.; Kruijtzer, J. A. W. Mol. Diversity
2004, 8, 79. (d) Langenhan, J. M.; Fisk, J. D.; Gellman, S. H. Org. Lett.
2001, 3, 2559. (e) Liskamp, R. M. J.; Rijkers, D. T. S.; Kruijtzer, J. A. W.;
Kemmink, J. ChemBioChem 2011, 12, 1626. (f) Turcotte, S.; Gervais,
S. H. B.; Lubell, W. D. Org. Lett. 2012, 14, 1318.
(4) (a) Seth Horne, W.; Gellman, S. H. Acc. Chem. Res. 2008, 41,
1399. (b) Martinek, T. A.; Fulop, F. Chem. Soc. Rev. 2012, 41, 687. (c)
Pilsl, L. K. A.; Reiser, O. Amino Acids 2011, 41, 709. (d) Vasudev, P. G.;
Chatterjee, S.; Shamala, N.; Balaram, P. Chem. Rev. 2011, 111, 657. (e)
Guichard, G.; Huc, I. Chem. Commun. 2011, 47, 5933. (f) Roy, A.;
Prabhakaran, P.; Baruah, P. K.; Sanjayan, G J. Chem. Commun. 2011,
47, 11593. (g) Prabhakaran, P.; Priya, G.; Sanjayan, G. J. Angew. Chem.,
Int. Ed. 2012, 51, 4006. (h) Nagel, L.; Plattner, C.; Budke, C.; Majer, Z.;
DeVries, A. L.; Berkemeier, T.; Koop, T.; Sewald, N. Amino Acids 2011,
41, 719.
r
10.1021/ol4002762
XXXX American Chemical Society